You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

April 20, 2015

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

FDA approves changes to hep C drug label to include new warnings

FDA has approved changes to the hepatitis C antiviral simeprevir (Olysio, Janssen) label to include new warnings about serious symptomatic bradycardia—slowing of the heart rate—when co-administered with antiarrhythmic drug amiodarone and antiviral sofosbuvir (Sovaldi, Gilead). » Details

FDA approves Corlanor to treat heart failure

FDA has approved ivabradine (Corlanor, Amgen) to reduce hospitalization due to worsening heart failure. » Read more

Continuing Education

2015 Updates on the national guidelines for diabetes management and related disorders

Last month and this month pharmacists will be able to learn about the latest developments in diabetes treatment and management. Pharmacists can earn up to 4 hours of CPE credit with two monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics. The goal of this month's activity is to discuss the recent updates of national U.S. guidelines for diabetes management, including hypertension and cholesterol management in patients with diabetes, in order to empower pharmacists in clinical decision-making.

Read/print the article: Click here

Take the test: Click here to log in with the Session Code 15DT16-TAJ88.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

FDA approves Copaxone for MS; problems persist

FDA approved the first generic version of Copaxone (glatiramer acetate injection) for treating patients with relapsing forms of multiple sclerosis (MS). » Read more

 

RELATED ARTICLES

Gilead sues to stop Actavis' generic bid for Letairis

Takeda announces post hoc analysis of data from EXAMINE cardiovascular safety outcomes trial

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group